Corporate ActionMay 4, 2026, 09:05 AM
Aura Biosciences Prices $260.3M Public Offering & Share Repurchase
AI Summary
Aura Biosciences priced an underwritten public offering of 39,591,000 shares of common stock and 3,800,000 pre-funded warrants, expecting gross proceeds of $260.3 million. The company plans to use $205.1 million of the net proceeds to advance clinical programs, including for early choroidal melanoma and bel-sar registration activities, and for general corporate purposes. The remaining net proceeds will fund the repurchase of up to 6,922,870 shares from Matrix Capital Management Master Fund, LP at $5.64 per share.
Key Highlights
- Priced public offering of 39,591,000 common shares at $6.00 each.
- Priced 3,800,000 pre-funded warrants at $5.99999 each.
- Expected gross proceeds from the offering are $260.3 million.
- Underwriters have a 30-day option to purchase an additional 6,508,650 shares.
- $205.1 million of net proceeds allocated to advance clinical programs and general corporate purposes.
- Remaining net proceeds to repurchase up to 6,922,870 shares from Matrix at $5.64 per share.
- Offering expected to close on or about May 5, 2026.